Technolgies
Innovative MedTech and Biotech Solutions for a Changing World
At S2Medical AB (publ), we specialize in cutting-edge technologies that drive innovation in wound healing, infection control and cosmeceuticals. Our portfolio consists of proprietary solutions that are scientifically validated and designed for both clinical and commercial success. By strategically balancing high-impact MedTech innovations with revenue-generating cosmetic technologies, we ensure sustainable growth and long-term value for investors and partners.
Our Core Technologies
Each technology in our portfolio addresses a specific need while presenting a scalable business opportunity.
Advanced Wound Treatments & Regenerative Medicine
IvaQ® – CE-marked Negative Pressure Wound Therapy (NPWT)
What it does:
IvaQ® is a next-generation negative pressure wound therapy (NPWT) system, developed to optimize healing outcomes by enhancing wound closure and reducing infection risks.
Value proposition:
CE-marked and ready for market introduction in 2025.
We are in the hunt for a distribution partnership with a global player, ensuring fast commercialization.
Addresses a multi-billion-dollar NPWT market with increasing global demand.
Instagraft®
– Revolutionizing Skin Grafting
What it does:
Instagraft® is a patented technology designed to make advanced skin transplantation more accessible, even in non-specialist healthcare settings. By simplifying the procedure, it opens up new possibilities for treating burns, chronic wounds, and reconstructive surgery. Instagraft® is a single-use medical device designed to treat chronic and complicated wounds with micro-transplants from the patient’s own skin without creating any new wounds.
This revolutionary device makes transplant treatment available to all patients and all healthcare professionals.
Value proposition:
A game-changing technology for skin repair, Instagraft® technology increases the donor: transplant ratio (up to 1:100)
Patent-protected with high licensing potential.
Reduces treatment complexity, making it scalable across healthcare markets.
Infection Control
ADMERCIN – Next-Generation Antimicrobial Peptide Technology
Background:
Antimicrobial Peptides (AMPs) represent a powerful class of natural defense molecules found in bacteria, fungi, plants, and animals. These peptides play a key role in the innate immune system, showing broad-spectrum activityagainst bacteria, viruses, and fungi. Their unique ability to disrupt microbial membranes makes them highly effective, while their low risk of resistance development positions them as a next-generation alternative to conventional antibiotics. At S2Medical, we are pioneering the development of AMP-based solutions for infection control, wound healing, and dermatological health. Our Admercin™ platform utilizes AMP technology to combat antibiotic-resistant infections, providing a new approach to treating chronic and acute wounds.
What it does:
ADMERCIN is a pharmaceutical innovation based on truncated antimicrobial peptides (AMPs), offering a powerful solution against antibiotic-resistant bacteria. The technology enhances the efficacy of existing antibiotics, making it a promising asset in the fight against antimicrobial resistance (AMR).
Innovative mechanism of Action:
ADMERCIN functions as an Electroselective Dispersant, selectively targeting bacterial membranes through a non-traditional pharmacological approach. Engineered to combat antibiotic-resistant infections, including the ESKAPE pathogens—among the most virulent and drug-resistant bacterial threats—ADMERCIN employs a dual mechanism of action:
Direct Bactericidal Activity – Disrupts bacterial membranes, leading to rapid eradication of resistant strains.
Synergistic Enhancement of Existing Antibiotics – Restores and amplifies the efficacy of conventional treatments against drug-resistant bacteria.
This novel approach not only ensures broad-spectrum antimicrobial activity but also significantly reduces the risk of pathogen escape and resistance evolution, addressing a critical challenge in modern infectious disease management.
Key Advantages:
Targeting ESKAPE Pathogens: Effective against Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species—the leading cause of nosocomial infections and antimicrobial resistance.
Bactericidal Effect: Directly eliminates multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, including carbapenem-resistant variants.
Resistance Mitigation: Multi-target mechanism disrupts bacterial survival pathways, reducing the likelihood of adaptive resistance.
Combination Therapy Potential: Enhances antibiotic efficacy, restoring activity against resistant bacteria and preventing treatment failure.
Strategic and Commercial Potential:
Addressing a WHO-Recognized Global Health Crisis: AMR is classified as a top 10 global health threat, with ESKAPE pathogens driving the highest morbidity and mortality in resistant infections.
Pharmaceutical Partnership Opportunity: Designed for co-development and licensing to accelerate clinical translation and market adoption.
High Market Potential: The antimicrobial therapeutics sector is projected to exceed $12 billion by 2030, with a growing demand for novel AMR solutions.
ADMERCIN represents a paradigm shift in antimicrobial therapy, directly tackling the most dangerous and treatment-resistant bacterial infections of our time.
Cosmetic & Functional Dermatology
Symbiovance™ – Peptide-Based Functional Skincare
What it does:
Symbiovance™ leverages cutting-edge peptide science to deliver functional dermatological solutions that go beyond traditional skincare. It is positioned for licensing and commercialization in collaboration with leading brands.
Value proposition:
Scientific precision meets skincare, differentiating it from conventional beauty products.
Strong potential for B2B licensing and white-label distribution.
Positioned for rapid revenue generation through the global cosmetic dermatology market.
Hair Repair
Eyracure – BIOlap20®
Eyracure is based on BIOlap20®, a patented light-activated peptide technology that repairs damaged hair at the molecular level. This innovation is already commercialized and rapidly expanding through partnerships with LYKO and other industry leaders. S2Medical is part owner (22,3%) of Eyracure AB
Material Technology
Eiratex®: Advanced Biosynthetic Polymer for Next-Generation Wound Healing Applications
Eiratex® is a proprietary biosynthetic material developed by S2Medical, and now owned by Epiprotect AB a company within the ABENA Group. Originally pioneered by S2Medical, this innovative polymer is composed of engineered sugar molecules, designed for precision and consistency at a molecular level. Its unique properties—superior conformability, transparency, mechanical strength, and breathability—set a new standard in wound management technologies.
The Epiprotect® dressing, made from Eiratex®, is one of the few advanced wound dressings with exceptional flexibility, enabling efficient treatment of facial burns and complex wounds. By regulating moisture across all phases of the healing process, it promotes an optimal wound environment while minimizing the need for frequent dressing changes. The nanostructure of Eiratex® mimics natural collagen, ensuring outstanding biocompatibility and enhancing cellular response.
Eiratex® is manufactured by S2Medical in a state-of-the-art, in-house production facility featuring five cleanroom areas. This facility adheres to SFS, LVFS, MDD and harmonized standards including ISO 13485, ensuring full regulatory compliance and superior quality control.
This breakthrough material is redefining the future of wound care, merging bioengineering with precision manufacturing to support faster healing and enhanced patient outcomes.
Made in SWEDEN, for the World.